Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens

Chromosome 1q21 aberration is one of the most common cytogenetic abnormalities in multiple myeloma, and is considered an important prognostic factor. The present study analyzed the clinical relevance and prognostic impact of 1q21 gain in 194 patients with newly diagnosed multiple myeloma treated wit...

Full description

Bibliographic Details
Main Authors: Xiao Liu, Shuangshuang Jia, Yuping Chu, Biao Tian, Yaya Gao, Chunyan Zhang, Yanhua Zheng, Weijing Jia, Xiangxiang Liu, Ruifeng Yuan, Na Zhang, Juan Feng, Hongjuan Dong, Xiaoli Xin, Ziwei Chang, Zhengcong Cao, Hailong Tang, Guangxun Gao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
multiple myeloma
1q21
bortezomib
cytogenetics introduction
prognostic factor and survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.938550/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.938550/full

Similar Items